Advertisement
U.S. markets close in 6 hours 5 minutes
  • S&P 500

    5,252.64
    +4.15 (+0.08%)
     
  • Dow 30

    39,760.88
    +0.80 (+0.00%)
     
  • Nasdaq

    16,410.80
    +11.28 (+0.07%)
     
  • Russell 2000

    2,120.30
    +5.96 (+0.28%)
     
  • Crude Oil

    82.36
    +1.01 (+1.24%)
     
  • Gold

    2,230.10
    +17.40 (+0.79%)
     
  • Silver

    24.75
    -0.01 (-0.03%)
     
  • EUR/USD

    1.0817
    -0.0013 (-0.12%)
     
  • 10-Yr Bond

    4.2220
    +0.0260 (+0.62%)
     
  • GBP/USD

    1.2646
    +0.0008 (+0.06%)
     
  • USD/JPY

    151.2410
    -0.0050 (-0.00%)
     
  • Bitcoin USD

    70,844.38
    +524.76 (+0.75%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,968.52
    +36.54 (+0.46%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Top Research Reports for UnitedHealth, Adobe & Amgen

Top Research Reports for UnitedHealth, Adobe & Amgen

Monday, September 17, 2018

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH), Adobe (ADBE) and Amgen (AMGN). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Buy-ranked UnitedHealth's shares have marginally underperformed the Zacks Medical Insurance industry's rally over the past year (up +33.9% vs. +35.1%). The Zacks analyst thinks UnitedHealth has been performing well on the back of solid performance by its UnitedHealthcare and Optum segments.

The company's robust Government is also driving long-term growth. Its international business and strong capital position driving business investment are the other positives. The company has been witnessing an increase in membership over the past many years.

Its raised 2018 earnings guidance should instill optimism among investors in the stock. However, the company is witnessing pressure in membership in its commercial business. Increasing consolidation will also heat up competition in the industry.

(You can read the full research report on UnitedHealth here >>>).

Shares of Adobe have gained +76.3% over the past year, outperforming the Zacks Software industry which has increased +38.7% over the same period. Adobe’s fiscal third-quarter results benefit from strong demand for its creative products. The company is currently benefiting from strong demand for its innovative solutions and growing subscriptions for its cloud application.

Adobe has been making great efforts toward establishing its presence in cloud-related software areas such as documents and marketing. Adobe Experience Manager, which enables brands to offer a personalized experience, is also witnessing robust growth.

The Zacks analyst remains optimistic about Adobe’s market position, compelling product lines, continued innovation, solid adoption of Creative Cloud and Adobe marketing cloud. However, lower end-market demand and exposure to Europe remain overhangs.

(You can read the full research report on Adobe here >>>).

Amgen’s shares have gained +15.4% year to date versus the Zacks Biomedical and Genetics industry's decline of -4.6%. Amgen’s newer drugs – Prolia, Xgeva, Blincyto, Repatha, Kyprolis – are performing well. Amgen is also progressing with its pipeline and the recent approval of migraine candidate, Aimovig was a huge boost.

The Zacks analyst thinks Amgen’s restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some bottom-line support in 2018. However, Amgen has some challenges in store, given the slowdown in sales of mature drugs like Enbrel, Aranesp and Neulasta, which are facing an array of branded and generic competitors.

Volume growth of new drugs may not be enough to offset lost sales due to the decline in mature brands. While Neupogen is already facing U.S. biosimilar competition, Neulasta, Epogen and Sensipar could start facing the same this year. Meanwhile, uptake of key new drug, Repatha has been slow due to payer restrictions.

(You can read the full research report on Amgen here >>>).

Other noteworthy reports we are featuring today include UPS (UPS), Accenture (ACN) and Bayer (BAYRY).

Best Electric Car Stock? You'll Never Guess It.

Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!

Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.

See Zacks Best EV Stock Free >>

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read

UnitedHealthcare & Optum Segments Aid UnitedHealth (UNH)

Adobe (ADBE) Counts on Creative Strength, Europe A Concern

Amgen (AMGN) Banks on New Drugs Amid Rising Competition

Featured Reports

E-Commerce, Dividends & Buybacks Aid UPS, Costs Ail

The Zacks analyst likes the company's efforts to reward shareholders. Growth in e-commerce is also a positive. However, high operating expenses are limiting bottom-line growth.

Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern

Per the Zacks analyst, Bayer continues to focus on acquisitions after completing the buyout of Monsanto in June 2018. However, generic competition remains a concern for the company.

New Personal Care Buys, Aging Populace Aid Amedisys (AMED)

The Zacks analyst is bullish about Amedisys' expanding customer base within Personal Care through strategic buyouts like Bring Care Home and ETPCS.

Fiber Solutions Segment to Aid Zayo Group Holdings (ZAYO)

Per the Zacks analyst, solid traction of Zayo's Fiber Solutions Segment, fueled by growing demand for cloud adoption and high-performance bandwidth, will continue to lend momentum to the company.

Semtech (SMTC) Benefits From End-Market Growth; Pricing Ails

Per the Zacks analyst, innovative products and strength in industrial and communications markets will drive Semtech.

Loan Growth, Streamlining Aid Zions (ZION), High Costs a Woe

Per the Zacks analyst, loan growth, higher interest rates and business restructuring initiatives continue to support Zions' profitability.

Dave & Buster's (PLAY) Rides on Expansion Amid Competition

The Zacks analyst sees Dave & Buster's continual efforts pursue a growth strategy in both new and existing markets as a major growth driver.

New Upgrades

Improving Retention Rate, Pay-TV Resizing Aids DISH (DISH)

Per the Zacks analyst, DISH's excellent customer service is improving retention. Also focus on acquiring and retaining subscribers that are profitable over the long term is paying off.

Robust Healthcare & Strategic Buyouts Aid FUJIFILM (FUJIY)

Per the Zacks analyst, FUJIFILM's buyout of Irvine Scientific Sales (ISUS) and IS JAPAN (ISJ) in April this year is helping the company to expand in the fast growing healthcare sector.

Accenture (ACN) Benefits from Acquisition of Reactive Media

The Zacks analyst believes that Accenture has strengthened its digital marketing capabilities through some significant acquisitions including Reactive Media, Acquity Group and dgroup.

New Downgrades

Copa Holdings (CPA) Stung by High Fuel Costs & Currency Woes

The Zacks analyst is concerned about the rise in fuel costs, which are limiting bottom-line growth. Currency devaluation in certain Latin American economies represent additional concerns.

Lower Production at Mount Milligan to Hurt Royal Gold (RGLD)

Per the Zacks analyst, Royal Gold's results will be hurt by inadequate water supplies and lower processing rates at Mount Milligan, resulting in deferred shipments and deliveries of gold and copper.

Soft Print Advertising Revenue a Worry for News Corp (NWSA)

News Corporation is grappling with soft print advertising demand. Per the Zacks analyst, the company needs to ramp up its presence in the digital space to offset the same.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
United Parcel Service, Inc. (UPS) : Free Stock Analysis Report
 
UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report
 
Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report
 
Amgen Inc. (AMGN) : Free Stock Analysis Report
 
Adobe Systems Incorporated (ADBE) : Free Stock Analysis Report
 
Accenture PLC (ACN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement